Chemotherapy Treatment Market Forecasts to 2030 – Global Analysis By Drug (Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Alkylating Agents, Mitotic Inhibitors, Antimetabolites and Other Drugs), Route of Drug, Dose, End User and By Geography

Chemotherapy Treatment Market Forecasts to 2030 – Global Analysis By Drug (Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Alkylating Agents, Mitotic Inhibitors, Antimetabolites and Other Drugs), Route of Drug, Dose, End User and By Geography

According to Stratistics MRC, the Global Chemotherapy Market is accounted for $8.81 billion in 2023 and is expected to reach $16.62 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Chemotherapy is a medical procedure that uses medications to either eliminate or slow the development of cancer cells in the body. It is a typical method of treating cancer and may be used alone or in combination with other treatments including surgery, radiation therapy, or immunotherapy. Chemotherapy medications target cells that divide quickly, including both cancer cells and some healthy cells. Unfortunately, as normal, healthy cells are also impacted by the treatment, this can result in a number of negative side effects, including nausea, hair loss, exhaustion, and a weaker immune system.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Cancer incidence has surged internationally, surpassing cardiovascular disease as the second greatest cause of death. Chemotherapy, the most common type of cancer treatment, is commonly coupled with other cancer medicines. Contrary to neo-adjuvant chemotherapy, which is administered prior to surgery and radiation therapy, adjuvant chemotherapy is used to reduce the tumor cell after surgery or radiation therapy. As a result, it is predicted that throughout the projected period, there will be a global increase in demand for oncology cancer medications.

Restraint:

Negative effects of drugs

Chemotherapy drugs kill healthy body cells while destroying malignant cells. This includes a number of unfavourable side effects for the individuals. Some common adverse effects include skin problems, hair loss, tiredness, neuropathies, and bone marrow suppression. A further disincentive will be the adverse effects of chemotherapy drugs, such as heart problems, low red blood cell counts, tiredness, hair loss, diarrhea, weight loss, impaired liver, kidney, and lung function, decreased bone density, and general ignorance. These are the elements limiting the market's expansion.

Opportunity:

Development of innovative technology

Chemotherapy has been essential in extending cancer patients' lives for a few more years than they otherwise would have. The most recent development in chemotherapy involves injecting drugs that treat cancer without hurting healthy cells into polluted regions. It has been demonstrated that using this technique keeps healthy tissue intact while removing cancerous cells. Using photon lasers, medical professionals may monitor the discharge of these nanoparticles into a patient's body and follow their duration and distribution while treating cancerous cells. This is the element propelling the segment's expansion.
Threat:

High associated costs

Chemotherapy is a medical procedure that uses medications to either eliminate or slow the development of cancer cells in the body. It is a typical method of treating cancer and may be used alone or in combination with other treatments. These medications target cells that divide quickly, including both cancer cells and some healthy cells. Unfortunately, as normal, healthy cells are also impacted by the treatment, this can result in a number of negative side effects. The high price of the chemotherapy drug will slow the market's expansion.

Covid-19 Impact:

The healthcare systems have been impacted by the COVID-19 pandemic, and the market has also been significantly impacted. The epidemic hampered the flow of drugs and medical supplies around the globe. This might have resulted in delays or shortages in the delivery of chemotherapy medications and other relevant medical supplies. Cancer research and clinical trials were briefly put on hold as a result of the pandemic as many institutes and pharmaceutical corporations concentrated on creating cures and vaccinations for COVID-19. This could have slowed down developments in cancer medicines like chemotherapy.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to be the largest during the forecast period. A medicine used to treat oral cancer comes in the form of a tablet, capsule, or liquid. The fastest growth rate was, however, seen with intravenous administration. Chemotherapy medications work faster because they are taken into the circulation promptly when given intravenously than when given orally or topically.

The leukemia segment is expected to have the highest CAGR during the forecast period

The leukemia segment is expected to have the highest CAGR during the forecast period. Slow-growing leukemias may require monitoring as part of their therapy. To treat severe leukemias, a combination of chemotherapy, radiation treatment, and stem cell transplantation may be employed. The rising incidence of breast cancer in women, the diversity of treatments available, and enhanced techniques for breast cancer diagnosis employing cutting-edge technology all contribute to the sector's expansion.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Chemotherapy is increasingly being preferred over other types of treatment because of its capacity to eradicate cancer cells. The market is primarily driven by the presence of multiple chemotherapy medication producers and an increase in healthcare spending. The market is also being driven by the accessibility of healthcare facilities and the use of cutting-edge technology in the investigation and treatment of cancer.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a result of expanded government awareness initiatives and g rowing healthcare costs in this area. Due to the availability of trained and competent healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic pharmaceuticals will also help to slow the market's rate of progress in this area. Government cancer insurance programs are anticipated to drive market growth. Government expenditure and a rise in the incidence of cancer will thus drive the market.

Key players in the market

Some of the key players in Chemotherapy market include AstraZeneca, GlaxoSmithKline, Novartis, Bayer AG, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Schering-Plough, Eli Lilly & Company, ImClone Systems Inc., Boehringer Ingelheim, E. Hoffmann-La Roche Ltd, Merck & Co. Inc., Chemo Espana SL, CELGENE CORPORATION, Sanofi, Teva Pharmaceuticals Industries, Pfizer Inc. and Amgen Inc.

Key Developments:

In October 2023, Novartis present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

In February 2023, Pfizer announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.

Drugs Covered:
• Anti-Tumor Antibiotics
• Topoisomerase Inhibitors
• Alkylating Agents
• Mitotic Inhibitors
• Antimetabolites
• Other Drugs

Route of Drugs Covered:
• Intravenous
• Oral
• Subcutaneous
• Intravascular
• Intra-Muscular
• Intraperitoneal
• Topical
• Intraventricular

Indications Covered:
• Colorectal Cancer
• Leukemia
• Prostate Cancer
• Breast Cancer
• Stomach Cancer
• Sarcoma
• Lung Cancer
• Myeloma
• Ovarian Cancer
• Lymphoma
• Other Indications

End Users Covered:
• Hospitals & Clinics
• Specialty Centers
• Research Institutes
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements